2 weeks ago
8
Soumya Eswaran
Fri, December 5, 2025 astatine 9:01 AM CST 3 min read
Deep Sail Capital, an concern absorption company, released its third-quarter capitalist letter. A transcript of the missive tin beryllium downloaded here. The money returned 5.8% nett of fees successful the 3rd quarter, outperforming the Russell 2000 Mid Cap Growth Index’s 0.4% instrumentality and lagging the Russell 2000 Index’s 12.4% gain. YTD, the money returned 18.1% nett of fees compared to 10.2% and 10.4% for the indexes. The agelong portfolio contributed to the fund's show successful the quarter, portion the abbreviated portfolio lagged amid the market's fervor. For much accusation connected the fund’s apical picks successful 2025, delight cheque its apical 5 holdings.
In its third-quarter 2025 capitalist letter, Deep Sail Capital highlighted stocks specified arsenic ClearPoint Neuro, Inc. (NASDAQ:CLPT). ClearPoint Neuro, Inc. (NASDAQ:CLPT) is simply a aesculapian instrumentality institution that focuses connected the improvement of platforms for performing minimally invasive surgical procedures. The one-month instrumentality for ClearPoint Neuro, Inc. (NASDAQ:CLPT) was -11.07%, and its shares gained 4.30% implicit the past 52 weeks. On December 04, 2025, ClearPoint Neuro, Inc. (NASDAQ:CLPT) banal closed astatine $14.06 per share, with a marketplace capitalization of $418.261 million.
Deep Sail Capital stated the pursuing regarding ClearPoint Neuro, Inc. (NASDAQ:CLPT) successful its 3rd 4th 2025 capitalist letter:
"The largest contributors successful Q3 were long-held microcap positions Kraken Robotics and ClearPoint Neuro, Inc. (NASDAQ:CLPT). Clearpoint besides had different large confirmatory caller event. uniQure (QURE) announced precise beardown proceedings results for its cistron therapy AMT-130 successful treating Huntington’s disease. The signifier 2 survey reported a ~75% slowing of illness progression implicit 3 years, which suggests that it mightiness beryllium a large measurement successful the absorption of curing Huntington’s disease. ClearPoint Neuro provides the SmartFlow Cannula strategy that uniQure volition usage for those treatments, and ClearPoint volition payment materially. uniQure volition apt beryllium the archetypal large neurological compartment & cistron therapy approved for 1 of the large neurological diseases. This is immense for Clearpoint and volition mean important milestone revenues arsenic good arsenic dense usage of their SmartFlow strategy successful the years to come."
ClearPoint Neuro, Inc. (NASDAQ:CLPT) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 10 hedge money portfolios held ClearPoint Neuro, Inc. (NASDAQ:CLPT) astatine the extremity of the 3rd quarter, the aforesaid arsenic successful the erstwhile quarter.While we admit the imaginable of ClearPoint Neuro, Inc. (NASDAQ:CLPT) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
English (CA) · 
English (US) · 
Spanish (MX) ·